but retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi Retatrutide - Research Dosing &
Description
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6

Furthermore, it slows gastric emptying, which moderates post-prandial glucose spikes, ensuring a steady release of nutrients into the bloodstream rather than an insulin-spiking surge

Plasma DPP-4 activity and TG excursion were reduced, and plasma active GLP-1 was increased, in sitagliptin-treated Dpp4 +/+ mice, but sitagliptin had no effect in Dpp4 / mice (Figure 1, B and C, and Supplemental Figure 3, A and B), consistent with the selectivity of sitagliptin for DPP-4 (22)

In animal work, we know that some neuronal regions regulating the impact of GLP-1 on food intake are distinct from those regions that regulate nausea (121, 129)

Dempsey described what happened with a long-term, difficult-to-treat patient shed been treating for about 20 years
An approved-drug precedent for how the approval pathway plays out.
